17:39 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the Phase I portion of a Phase I/II trial showing that twice-daily 400-800 mg doses of oral CB-839 plus Xeloda...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
19:02 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest the GLS inhibitor CB-839 could help treat KRAS-mutant lung cancers that also harbor KEAP1 mutations. In a mouse model of KRAS- and KEAP1-mutant lung cancer, the GLS...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction; neurology Mouse and pig studies identified a GLS inhibitor prodrug that could help treat HIV-associated neurocognitive disorders. In a mouse model of HIV-associated neurocognitive dysfunction, the GLS inhibitor 6-diazo-5-oxo-L-norleucine (DON) increased spatial learning...
23:10 , Mar 22, 2017 |  BC Extra  |  Financial News

RegenxBio, Adaptimmune, Calithera price follow-ons

RegenxBio Inc. (NASDAQ:RGNX), Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Calithera Biosciences Inc. (NASDAQ:CALA) each priced follow-on offerings, raising a total of $206 million. Gene therapy play RegenxBio raised $75.9 million through the sale of 3.7 million shares...
22:29 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

CB-839: Updated Ph I CX-839-001 data

Updated data from a cohort of 16 evaluable patients with metastatic triple-negative breast cancer (TNBC) in the open-label, dose-escalation U.S. Phase I CX-839-001 trial showed that twice-daily 600 and 800 mg oral CB-839 plus paclitaxel...
21:48 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

CB-839: Updated Ph I data

Updated data from a cohort of 15 evaluable patients with renal cell carcinoma (RCC) in the open-label, dose-escalation, U.S. Phase I CX-839-001 trial showed that 400-800 mg CB-839 twice daily plus 10 mg oral Afinitor...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); glutaminase (GLS)

Cardiovascular disease INDICATION: Hypertension Rat studies suggest inhibiting YAP or GLS could help treat pulmonary arterial hypertension (PAH). In a rat model of PAH, Visudyne verteporfin, a YAP inhibitor, decreased pulmonary vascular proliferation and remodeling, right ventricular...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glutaminase (GLS)

Cancer INDICATION: Pancreatic cancer Mouse studies suggest combining metformin and GLS inhibitor-loaded nanoparticles could help treat pancreatic cancer. In a patient-derived xenograft mouse model of pancreatic cancer, the GLS inhibitor CB-839 or a GLS inhibitor tool compound...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

CB-839: Phase I/II started

Calithera began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate oral CB-839 plus IV Opdivo nivolumab in about 242 patients with solid tumors, including clear cell renal cell carcinoma (ccRCC), melanoma and non-small...